

Ref: GLL/Board/2019-20/0017

Date: 14/08/2019.

To
Dy. General Manager,
BSE Ltd.,
Phiroje Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To
Asst. Manager (Listing)
The Ahmedabad Stock Exchange Ltd.,
Kamdhenu Complex, Opp.Sahajanand College,
Ahmedabad – 380 015.

To
The Secretary
The Calcutta Stock Exchange Association Ltd.,
7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject : Announcement of Un-audited financial results for the Quarter Ended
June 30, 2019 together with the Limited Review Report of Auditors
as Annexure – I.

Reference : Reg. 30(2) and Reg.33 of SEBI (LODR) Regulations, 2015.


This is to inform you that the Un-audited financial results Standalone & Consolidated for the quarter ended June 30, 2019 was approved and taken on records by the Board of Directors at their meeting held on August 14, 2019. The same was signed by Mr. T.M.Gopalakrishnan, Whole Time Director of the Company and we enclose Un-audited financial results for the quarter ended June 30, 2019 together with Limited Review Report as Annexure – I. We are arranging publication of the results in the newspaper and also in the website of the Company as required under Reg.33 read with 47 of SEBI (LODR) Regulations, 2015.

The Meeting commenced at 04.30 P.M. and concluded at 08.50 P.M.

Kindly bring this to the notice of the members of the Exchange.

Thanking You,

Yours faithfully,
For Gennex Laboratories Ltd.,


Authorised Signatory

Encl: a/a.

Gennex Laboratories Limited



GENNEX LABORATORIES LIMITED
Registered Office : Sy.No.133, Bollaram, Jinnaram Mandal,
Dist : Sangareddy, Telangana - 502 325. INDIA
Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com
CIN : L24230TG1990PLC011168

Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2019

(Rs. In Lacs)

| S No. | PARTICULARS | Standalone | | | | Consolidated | | | |
|-------|---|---------------------------|-------------------------|---------------------------|-------------------------|---------------------------|-------------------------|---------------------------|-------------------------|
| | | Quarter ended | | Year ended | | Quarter ended | | Year ended | |
| | | 30.06.2019 (Unaudited) | 31.03.2019 (Audited) | 30.06.2018 (Unaudited) | 31.03.2019 (Audited) | 30.06.2019 (Unaudited) | 31.03.2019 (Audited) | 30.06.2018 (Unaudited) | 31.03.2019 (Audited) |
| 1 | Income | | | | | | | | |
| | Revenue from Operations | 1608.73 | 2036.07 | 944.49 | 5580.27 | 1608.73 | 2036.07 | 944.49 | 5580.27 |
| | Other Income | 34.18 | 25.03 | 14.43 | 78.25 | 34.18 | 25.03 | 14.43 | 78.25 |
| | Total Income | 1642.91 | 2061.10 | 958.92 | 5658.52 | 1642.91 | 2061.10 | 958.92 | 5658.52 |
| 2 | Expenses | | | | | | | | |
| (a) | Cost of material consumed | 1030.07 | 1213.16 | 618.98 | 3468.05 | 1030.07 | 1213.16 | 618.98 | 3468.05 |
| (b) | Purchase of stock-in-trade | 0.00 | 37.59 | 0.00 | 40.52 | 0.00 | 37.59 | 0.00 | 40.52 |
| (c) | Changes in stock-in-trade and Work in Progress and stock in trade | -97.55 | -18.52 | -97.17 | -238.82 | -97.55 | -18.52 | -97.17 | -238.82 |
| (d) | Employees Cost | 170.13 | 180.78 | 128.09 | 612.20 | 170.13 | 180.78 | 128.09 | 612.20 |
| (e) | Depreciation | 25.42 | 19.46 | 24.02 | 98.47 | 25.42 | 19.46 | 24.02 | 98.47 |
| (f) | Finance Cost | 22.92 | 20.29 | 16.99 | 79.38 | 22.92 | 20.29 | 16.99 | 79.38 |
| (g) | Other Expenses | 385.18 | 483.06 | 220.64 | 1296.00 | 385.18 | 483.06 | 220.64 | 1296.00 |
| | Total Expenses | 1536.17 | 1935.82 | 911.55 | 5355.80 | 1536.17 | 1935.82 | 911.55 | 5355.80 |
| 3 | Total Profit before exceptional Items & Tax. | 106.74 | 125.28 | 47.37 | 302.72 | 106.74 | 125.28 | 47.37 | 302.72 |
| 4 | Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 | Total profit before tax | 106.74 | 125.28 | 47.37 | 302.72 | 106.74 | 125.28 | 47.37 | 302.72 |
| 6 | Tax expense for earlier years | 0.00 | -0.15 | 0.00 | -0.15 | 0.00 | -0.15 | 0.00 | -0.15 |
| 7 | Curent tax | -27.00 | -85.00 | 0.00 | -85.00 | -27.00 | -85.00 | 0.00 | -85.00 |
| 8 | Deferred Tax | 0.00 | 4.51 | 0.00 | 4.51 | 0.00 | 4.51 | 0.00 | 4.51 |
| 9 | Total Tax Expenses | -27.00 | -80.64 | 0.00 | -80.64 | -27.00 | -80.64 | 0.00 | -80.64 |
| 10 | Net profit (Loss) | 79.74 | 44.64 | 47.37 | 222.08 | 79.74 | 44.64 | 47.37 | 222.08 |
| 11 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 | 0.00 | 0.00 | (0.84) | (8.08) | - | (8.08) |
| 12 | Total Profit (loss) for period | 79.74 | 44.64 | 47.37 | 222.08 | 78.90 | 36.56 | 47.37 | 214.00 |
| 13 | Other comprehensive income net of taxes | | | | | | | | |
| 14 | Total Comprehensive income for the period | | | | | | | | |
| | Total profit or loss, attributable to | | | | | | | | |
| | Profit or loss, attributable to owners of parent | | | | | | | | |
| 15 | Total Comprehensive income for theperiod attributable to | | | | | | | | |
| | Comprehensive income for the period attributable to owners of parent | | | | | | | | |
| | Total comprehensive income for the period attrributable to owners of parent non controlling interests | | | | | | | | |
| 16 | Details of equity share capital | | | | | | | | |
| | Paid up equity share capital | 1265.03 | 1265.03 | 1265.03 | 1265.03 | 1265.03 | 1265.03 | 1265.03 | 1265.03 |
| | Face value of equity share capital | 0.00001 | 0.00001 | 0.00001 | 0.00001 | 0.00001 | 0.00001 | 0.00001 | 0.00001 |
| 17 | Earnings per share | | | | | | | | |
| | - Basic | 0.063 | 0.035 | 0.037 | 0.176 | 0.062 | 0.029 | 0.037 | 0.169 |
| | - Diluted | 0.063 | 0.035 | 0.037 | 0.176 | 0.062 | 0.029 | 0.037 | 0.169 |

Notes to the results:

- The above audited financial results have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors
- The statement has been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of Companies Act, 2013 and other prescribed accounting practices and policies to the extent possible.
- The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reporable segment namely " Bulk Drugs,Biotech Products and Intermediates".
- Provision for Taxation & IAS-12 Deferred Tax will be made at the end of the year.
- Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- The Figures for the Quarter ended 31-March-2019 and the corresponding quarter ended in the Previous year, as reported in these financial results, are the blancing figures between audited figures in respect of the full financial year and the published year to data figures upto the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit. Previously period/year figures have been regrouped/reclassified wherever necessary.

**For and on behalf of the Board
For Gennex Laboratories Limited**

**Sd/-
T.M.Gopalakrishnan
Whole Time Director**

Place: Hyderabad
Date: 14.08.2019

Limited Review report

To
The Board of Directors,
Gennex Laboratories Limited,
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of **Gennex Laboratories Limited** for the Quarter ended 30th June 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **PPKG & Co.**
Chartered Accountants
FRN No. 09655s

Girdhari Lal Toshniwal

Girdhari Lal Toshniwal
(Partner)

M.No. 205140

UDIN: 19205140AAAABT7145



Place: Hyderabad
Date: 14/08/2019

Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To The Board of Directors,
Gennex Laboratories Limited,
Hyderabad.

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Gennex Laboratories Limited ("the Company") and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associate for the quarter ended 30th June 2019 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30th June 2019 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of **Deccan Remedies Limited**.




Cont... 2

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Associate, which have been reviewed by their auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 0.00 lakhs, total net loss after tax of Rs. 1.89 lakhs and total comprehensive loss of Rs. 0.00 lakhs, for the quarter ended June 30, 2019 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of these Associates, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For **PPKG & Co**
Chartered Accountants
FRN No. 009655s


Girdhari Lal Toshniwal
(Partner)
M.No. 205140
UDIN: 19205140AAAABT7145



Place: Hyderabad
Date: 14/08/2019